<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654702</url>
  </required_header>
  <id_info>
    <org_study_id>HM-MONT-OS-01</org_study_id>
    <nct_id>NCT04654702</nct_id>
  </id_info>
  <brief_title>Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap.</brief_title>
  <official_title>A Multi-center, Prospective, Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap in Patients With Asthma and Perennial Allergic Rhinitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigator examines the past prescription patterns and the reasons for the change of&#xD;
      prescription to Monterizine capsules for Perennial Allergic Rhinitis patients with Asthma who&#xD;
      will be taking Monterizine capsules to treat allergic rhinitis.&#xD;
&#xD;
      After being given Monterizine capsules, Investigator evaluates the therapeutic effectiveness&#xD;
      and safety for 3 months (or 6 months).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi-center, Prospective, Observational Study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 17, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The change in the average of TNSS at the point of Period 1 (recommended 3 Month(-1 Month)) as compared to baseline</measure>
    <time_frame>3 Month</time_frame>
    <description>The change in the average of TNSS at the point of Period 1 (recommended 3 Month(-1 Month)) as compared to baseline.&#xD;
*TNSS: Total symptom scores for nasal congestion, sneezing, runny nose and nasal itching during the daytime in the past week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in the average of TNSS at the point of Period 2(recommended 6Month(±1Month)) as compared to baseline</measure>
    <time_frame>6Month</time_frame>
    <description>The change in the average of TNSS at the point of Period 2(recommended 6Month(±1Month)) as compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the therapeutic satisfaction at the point of Period 1 (recommended 3Month(-1Month)), Period 2(recommended 6Month(±1Month)) as compared to baseline</measure>
    <time_frame>3Month,6Month</time_frame>
    <description>The change in the therapeutic satisfaction at the point of Period 1 (recommended 3Month(-1Month)), Period 2(recommended 6Month(1±Month)) as compared to baseline.&#xD;
*Therapeutic satisfaction : overall satisfaction with the treatment of allergic rhinitis for the past month. A possible scale is then: &quot;Very Satisfied&quot;, &quot;Satisfied&quot;, &quot;Neutral&quot;, &quot;Dissafistied&quot;, &quot;Very Dissatisfied&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the quality of life at the point of Period 1 (recommended 3Month(-1Month)), Period 2(recommended 6Month(±1Month)) as compared to baseline</measure>
    <time_frame>3Month,6Month</time_frame>
    <description>The change in the quality of life at the point of Period 1 (recommended 3Month(-1Month)), Period 2(recommended 6Month(±1Month)) as compared to baseline.&#xD;
*Evaluate the quality of life with KARQLQ (Korean allergic rhinitis-specific quality of life questionnaire: 10 questions in regular activities at home and work, daily life disturbance and other symptoms)in the past week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the medication compliance at the point of Period 1 (recommended 3Month(-1Month)), Period 2(recommended 6Month(±1Month)) as compared to baseline</measure>
    <time_frame>3Month,6Month</time_frame>
    <description>The change in the medication compliance at the point of Period 1 (recommended 3Month(-1Month)), Period 2(recommended 6Month(±1Month)) as compared to baseline.&#xD;
*Assessing the medication compliance for the last 30 days; compliance⪴80%, non-compliance&lt;20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and frequency of adverse events</measure>
    <time_frame>6Month</time_frame>
    <description>Occurrence and frequency of adverse events</description>
  </secondary_outcome>
  <enrollment type="Actual">2671</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <condition>Asthma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        3,000 patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged ≥ 15 years&#xD;
&#xD;
          2. Perennial allergic rhinitis patients with asthma who will be prescribed Monterizine&#xD;
             capsules to treat allergic rhinitis&#xD;
&#xD;
          3. Patients who provided a signed written informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Highly sensitive patients to ingredients of Monterizine capsules, hydroxyzine or&#xD;
             piperazine derivatives&#xD;
&#xD;
          2. Patients with renal failure(CLCR,10ml/min) and hemodialysis patients&#xD;
&#xD;
          3. A female who is pregnant, may be pregnant, or is lactating&#xD;
&#xD;
          4. Patients with genetic problems like Galactose intolerance, Lapp lactase deficiency or&#xD;
             Glucose-galactose malabsorption&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byoung-Whui Choi</last_name>
    <role>Principal Investigator</role>
    <affiliation>59 institutions including Chung-Ang University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>59 institutions including Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

